Immune checkpoint inhibitor-related myocarditis and meningoencephalitis induced by toripalimab - a case report and review of the literature
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced lung cancer, particularly in patients with advanced or locally advanced non-small cell lung cancer. Toripalimab, a humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, has demonstrated promising antitumor activity since its first official approval for the treatment of lung cancer in September 2022; however, like other ICIs, toripalimab may also induce immune-related adverse events (irAEs). Owing to its relatively short time on the market and the potential underreporting of some rare toxicities, the full safety profile of toripalimab has not yet been completely characterized. Reports of severe toripalimab-related myocarditis complicated by meningoencephalitis remain rare. By presenting this case and reviewing the relevant literature, this article aims to improve clinicians’ awareness of these potentially life-threatening immune-related toxicities and to facilitate their early recognition and timely management.
Authors
- Xinmiao Zhou (ORCID: https://orcid.org/0000-0003-2235-0338)
- Zhuo Cao (ORCID: https://orcid.org/0000-0003-4506-190X)
- Huamei Fan
- Pan Ye
Institutions
- Sir Run Run Shaw Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fmed.2026.1977093
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00